Search - tctmd.com

Displaying 761 - 780 of 806

Sort: Relevancy | Date

Presentation CTO 2012

Dedicated Left Main Bifurcation Stents 1: Rationale, Landscape, and Development

Presenter: Martin Leon

February 22, 2012

Presentation CTO 2012

Can IVUS Help Determine Whether One vs. Two Stents Are Necessary?

Presenter: Akiko Maehara

February 22, 2012

Presentation CTO 2012

Can FFR Help Determine Whether One vs. Two Stents Are Necessary?

Presenter: Morton Kern

February 22, 2012

Presentation

Oclusión con Balón Proximal frente al Filtro de Protección Embólica en Pacientes Sometidos a Colocación de Stents en la Carótida (CAS)

Presenter: K. Bijuklic

January 25, 2012

Presentation

Ensayo Aleatorizado Multicentro Comparador de Amfilimus con Stents Liberadores de Paclitaxel en Lesiones Coronarias Nativas De Novo

Presenter: Didier Carri?

January 24, 2012

Presentation

A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions

Presenter: Didier Carrie

January 24, 2012

Presentation ISET 2012

Second- and Third-generation DES: Are All Coated Stents Equal?

Presenter: Eberhard Grube

January 15, 2012

Presentation ISET 2012

Drug-coated Balloons and Stents in the Periphery: Is There a Future?

Presenter: Ron Waksman

January 15, 2012

Presentation TCT 2012

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Presenter: Hirotoshi Watanabe, Kyohei Yamaji, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Koyu Sakai, Katsuhiro Kondo, Masashi Iwabuchi, Hiroyoshi Yokoi, Hideyuki Nosaka, Masakiyo Nobuyoshi

January 03, 2012

Presentation TCT 2012

Two-Year Outcomes of a Propensity-Matched Comparison of the ION and TAXUS Liberté Paclitaxel-Eluting Stents.

Presenter: Dean J. Kereiakes, Louis A. Cannon, John A. Ormiston, Hong Wang, Paul L. Underwood, Keith D. Dawkins

January 03, 2012

Presentation TCT 2012

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

Presenter: SunWon Kim, Seung Woon Rha, Byoung Geol Choi, Amro Elnagar, Sung Il Im, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh

January 03, 2012

Presentation TCT 2012

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

Presenter: Juan Luis Guti?rrez-Chico, Lorenz R?ber, Evelyn Regar, Takayuki Okamura, Carlo di Mario, Stephan Windecker, Gerrit-Anne van Es, Patrick W. Serruys

January 03, 2012

Presentation TCT 2012

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Presenter: Ted S. Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski

January 03, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Presentation TCT 2012

Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model

Presenter: Li Shen, Qibing Wang, Yizhe Wu, Jian Xie, Junbo Ge

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Presenter: Hao Xu, Kytai T. Nguyen, Lance S. Terada, Eric Fuh, Joseph A. Garcia, Emmanouil S. Brilakis, Deepak L. Bhatt, Subhash Banerjee

January 03, 2012

Presentation TCT 2012

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Presenter: Boris Rudenko, Anatoly Savchenko, Serdgey Tereshchenko, Olga Cherkavskaya

January 03, 2012

Presentation TCT 2012

Pharmacokinetic Evaluation of Drug Eluting Stents in a Healthy and Atherosclerotic Rabbit Iliac Model

Presenter: Alexander Sheehy, Saami K. Yazdani, Ed Berger, Rosy S. Donn, Tu D. Ngo, Stephen Pacetti, Syed Hossainy, Frank D. Kolodgie, Renu Virmani

January 03, 2012

Advertisement

Dedicated Left Main Bifurcation Stents 1: Rationale, Landscape, and Development

Can IVUS Help Determine Whether One vs. Two Stents Are Necessary?

Can FFR Help Determine Whether One vs. Two Stents Are Necessary?

Oclusión con Balón Proximal frente al Filtro de Protección Embólica en Pacientes Sometidos a Colocación de Stents en la Carótida (CAS)

Ensayo Aleatorizado Multicentro Comparador de Amfilimus con Stents Liberadores de Paclitaxel en Lesiones Coronarias Nativas De Novo

A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions

Second- and Third-generation DES: Are All Coated Stents Equal?

Drug-coated Balloons and Stents in the Periphery: Is There a Future?

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Two-Year Outcomes of a Propensity-Matched Comparison of the ION and TAXUS Liberté Paclitaxel-Eluting Stents.

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Pharmacokinetic Evaluation of Drug Eluting Stents in a Healthy and Atherosclerotic Rabbit Iliac Model

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content